Marsha Reyngold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marsha Reyngold has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Eileen Mary O'Reilly
Weill Cornell Medicine
58 shared publications - Christine Iacobuzio-Donahue
The David M Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY
54 shared publications - Christopher H. Crane
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
48 shared publications - Wungki Park
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
35 shared publications - Fiyinfolu Balogun
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
32 shared publications - Kenneth H. Yu
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
29 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS allele-specific targeted trials in pancreatic cancer—select completed and ongoing.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS allele-specific targeted trials in pancreatic cancer—select completed and ongoing.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS multi-allele and immune-targeted trials in pancreatic cancer—select completed and ongoing.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS multi-allele and immune-targeted trials in pancreatic cancer—select completed and ongoing.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
MAPK pathway targeting for pancreatic cancer. [Created in BioRender. Rubenstein, D. (2025) https://BioRender.com/27s6pcf.]
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
MAPK pathway targeting for pancreatic cancer. [Created in BioRender. Rubenstein, D. (2025) https://BioRender.com/27s6pcf.]
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Pancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents.Significance:PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents.Significance:PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Mechanisms of KRAS inhibitor/degrader.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Mechanisms of KRAS inhibitor/degrader.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Current treatment regimens for pancreatic cancer.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Current treatment regimens for pancreatic cancer.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (7) , 1262-1279
Pancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents. Significance: PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (7) , 1262-1279
Open AccessPancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents. Significance: PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S1 shows frequency distribution of estimated CCF values for all major driver genes selected in this study.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S1 shows frequency distribution of estimated CCF values for all major driver genes selected in this study.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S11 shows 2 × 2 contingency table to calculate p-value for pathway analysis.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Figure S11 shows 2 × 2 contingency table to calculate p-value for pathway analysis.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S4 shows list of genetic details and clonality of KRAS and TP53 mutations in our PDAC cohort.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Supplementary Table S4 shows list of genetic details and clonality of KRAS and TP53 mutations in our PDAC cohort.